EUVIMEDEUVIMED entdecken
Open Access

Proteasome Inhibitor–Induced Cytotoxic Mechanisms in Canine Pulmonary Adenocarcinoma Cell Lines

Aika Chijiwa, Sakuya Inanaga, Tomohiro Osaki, Masaya Igase, Takuya Mizuno

Veterinary and Comparative Oncology · 2026-09 · 24 (3) · 421-432

DOI: 10.1111/vco.70065 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Veterinary and Comparative Oncology, online erschienen am 06.04.2026. Verfasst von Aika Chijiwa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan. Hauptthemen laut MEDLINE: Proteasome Inhibitors, Lung Neoplasms, Antineoplastic Agents, Adenocarcinoma. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Canine pulmonary adenocarcinoma (cPAC) lacks well‐validated systemic treatment options, motivating preclinical identification of potential therapeutic candidates. To explore potential therapeutic candidates, we first performed a screening of an FDA‐approved drug library using a cPAC cell line, which identified bortezomib—a proteasome inhibitor—as a potential agent. Guided by this result, we focused subsequent investigations on proteasome blockade and evaluated the antitumor activity and mechanisms of bortezomib together with a second‐generation proteasome inhibitor, carfilzomib—alone and in combination with standard cytotoxics—in three cPAC cell lines (CLAC, HDC, and LuBi). Both agents reduced cell proliferation and cell viability in a dose‐dependent manner, with proteasome target engagement (ubiquitinated protein accumulation), G2/M arrest, sub‐G1 increase, and caspase‐3 cleavage. Pan‐ and selective caspase inhibition partially rescued viability, suggesting contributions from both intrinsic and extrinsic apoptosis, together with caspase‐independent mechanisms. We also observed activation of the JNK–c‐Jun pathway and increased Bim expression, indicating the induction of cellular stress responses and apoptosis. Drug‐interaction analysis showed reproducible synergy between carfilzomib and carboplatin in HDC and LuBi, whereas combinations with vinorelbine were mainly additive or antagonistic effects. Overall, proteasome inhibitors exert multifaceted cytotoxic effects in cPAC through proteotoxic stress, cell‐cycle arrest, and caspase‐associated apoptosis. In particular, the combination of carfilzomib and carboplatin may represent a promising therapeutic strategy. Further in vivo and clinical investigations are warranted to evaluate therapeutic efficacy, safety, and pharmacokinetics of proteasome inhibitors in cPAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proteasome InhibitorsLung NeoplasmsAntineoplastic AgentsAdenocarcinomaDog DiseasesAnimalsDogsOligopeptidesCell Line, TumorBortezomibApoptosisCell SurvivalCell Proliferation

Stichwörter der Autor:innen

apoptosisdogsdrug combinationproteasome inhibitorsproteotoxic stresspulmonary cancer

Substanzen

Proteasome InhibitorscarfilzomibOligopeptidesAntineoplastic AgentsBortezomib

Autor:innen und Institutionen

  • Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan.
  • Laboratory of Molecular Diagnostics and Therapeutics, Joint Graduate School of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan.
  • Joint Department of Veterinary Medicine, Faculty of Agriculture, Tottori University, Tottori, Japan.
  • Japan Small Animal Cancer Center, Public Interest Incorporated Foundation Japan Small Animal Medical Center, Saitama, Japan.
  • Division of Translational Research for One Medicine, Research Institute for Cell Design Medical Science, Yamaguchi University, Yamaguchi, Japan.

Zitieren

APA

Chijiwa, A., Inanaga, S., Osaki, T., Igase, M., & Mizuno, T. (2026). Proteasome Inhibitor–Induced Cytotoxic Mechanisms in Canine Pulmonary Adenocarcinoma Cell Lines. Veterinary and Comparative Oncology, 24(3), 421-432. https://doi.org/10.1111/vco.70065

Vancouver

Chijiwa A, Inanaga S, Osaki T, Igase M, Mizuno T. Proteasome Inhibitor–Induced Cytotoxic Mechanisms in Canine Pulmonary Adenocarcinoma Cell Lines. Veterinary and Comparative Oncology. 2026;24(3):421-432. doi:10.1111/vco.70065

BibTeX
@article{Chijiwa2026,
  author = {Chijiwa, Aika and Inanaga, Sakuya and Osaki, Tomohiro and Igase, Masaya and Mizuno, Takuya},
  title = {Proteasome Inhibitor–Induced Cytotoxic Mechanisms in Canine Pulmonary Adenocarcinoma Cell Lines},
  journal = {Veterinary and Comparative Oncology},
  year = {2026},
  volume = {24},
  number = {3},
  pages = {421--432},
  doi = {10.1111/vco.70065}
}
Kostenlos starten →